Active, not recruitingPhase 1NCT06645886
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kumquat Biosciences Inc.
- Intervention
- KQB198(drug)
- Enrollment
- 13 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (29)
- University of California, San Francisco (UCSF), San Francisco, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Oncology Hematology Cincinnati, Cincinnati, Ohio, United States
- Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations, Nashville, Tennessee, United States
- Texas Oncology Austin Central, Austin, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- CHRU de Tours - Hopital Bretonneau, Tours, Centre-Val de Loire, France
- AP-HM - Hopital de la Timone, Marseille, France
- Medizinische Hochschule Hannover (MHH), Hanover, Lower Saxony, Germany
- Universitaetsklinikum Jena, Jena, Thuringia, Germany
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola, Bologna, Bologna, Italy
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06645886 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics